New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
14:21 EDTACTActavis price target raised to $198 from $180 at Argus
Argus increased its price target on Actavis after raising its 2013 adjusted EPS estimate above the company's guidance. The firm is upbeat about the outlook for generic drug companies in general, and predicts that Actavis will deliver mid-teens organic earnings growth in the near-term. It keeps a Buy rating on the stock.
News For ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent ACT news | >>
February 19, 2015
07:44 EDTACTActavis to sell 4.2B ordinary shares and $4.2B convertible preferred shares
Subscribe for More Information
07:40 EDTACTActavis price target raised to $352 from $300 at Canaccord
Subscribe for More Information
07:39 EDTACTActavis price target raised to $328 from $310 at Leerink
Subscribe for More Information
07:28 EDTACTActavis files automatic mixed securities shelf
Subscribe for More Information
February 18, 2015
16:46 EDTACTOn The Fly: Closing Wrap
Subscribe for More Information
12:31 EDTACTOn The Fly: Midday Wrap
Subscribe for More Information
09:48 EDTACTActavis Q4 'exceptional,' taking Allergan name 'wise,' says BMO Capital
BMO Capital says Actavis (ACT) is "firing on all cylinders" after reporting "exceptional" Q4 earnings on the strength of the company's North American Generics and International segment. BMO views the decision to adopt the Allergan (AGN) name as "wise" given the Botox maker's strong reputation. The firm keeps an Outperform rating on Actavis.
07:50 EDTACTActavis CEO says company gave appropriate guidance to analysts
Actavis (ACT) CEO Saunders said he believes that the company did provide appropriate guidance to analysts ahead of its earnings beat. Saunders sees the Allergan (AGN) deal closing by the end of this quarter or early next quarter. Saunders says tying R&D to a percentage of revenue "makes no sense to me," noting that Actavis will spend about $1.7B on R&D next year. Saunders says will do acquisition if opportunity arises, but not planning for M&A right now. Actavis CEO Brent Saunders is speaking on CNBC.
07:01 EDTACTActavis announces intention to adopt 'Allergan' corporate name
Subscribe for More Information
06:48 EDTACTActavis reports 9 mid-to-late-stage compounds in development
Subscribe for More Information
06:34 EDTACTActavis sees Allergan transaction completed in late Q1 or early Q2
06:33 EDTACTActavis sees FY15 standalone EPS $16.30-$17.30, consensus $16.63
Subscribe for More Information
06:31 EDTACTActavis reports Q4 EPS $3.91, consensus $3.67
Subscribe for More Information
February 17, 2015
18:17 EDTACTJANA Partners gives quarterly update on stakes
NEW STAKES: NCR (NCR), Liberty Ventures (LVNTA), Solarcity (SCTY), Computer Sciences Corp (CSC), Salix (SLXP), and Applied Materials (AMAT). INCREASED STAKES: Hertz (HTZ), Valeant (VRX), Walgreens Boots Alliance (WBA), Rackspace (RAX), and HD Supply (HDS). DECREASED STAKES: AIG (AIG), Actavis (ACT), Charter (CHTR), AerCap (AER), and Energy Transfer Equity (ETE). LIQUIDATED STAKES: Equinix (EQIX), Cameron International (CAM), Dollar General (DG), QEP Resources (QEP), and Amgen (AMGN).
18:06 EDTACTPaulson & Co gives quarterly update on stakes
Subscribe for More Information
17:16 EDTACTActavis confirms temporary injunction related to generic Pulmicort RESPULES
Subscribe for More Information
17:02 EDTACTSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
15:32 EDTACTNotable companies reporting before tomorrow's open
Subscribe for More Information
13:52 EDTACTEarnings Preview: Actavis near 52-week high ahead of Q4 earnings report
Subscribe for More Information
13:18 EDTACTOmega Advisors gives quarterly update on stakes
Subscribe for More Information
1 | 2 | all recent ACT news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use